Veloxis wins Orphan Drug status
Veloxis’ Envarsus XR has been awarded FDA’s Orphan Drug status. It could lead to tax benefits and higher sales prices, says an analyst, stressing, however, that the company remains strapped for cash.
BY STEFAN SINGH KAILAY & BENJAMIN WERNER CHRISTENSEN
Denmark’s Veloxis ended last week with a bit of good news, as it announced that FDA has granted Orphan Drug status for its drug Envarsus XR for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Veloxis loses legal battle with FDA
For abonnenter
Here is the time frame for Veloxis' FDA case
For abonnenter
FDA rejects Veloxis again
For abonnenter
